BioLineRx (BLRX) Revenue (2024 - 2026)
BioLineRx (BLRX) posted quarterly Revenue of $194000.0 for Q4 2025, down 98.35% year-over-year from $11.7 million in Q4 2024, and down 54.57% quarter-over-quarter from $427000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Revenue (2024 - 2026) Analysis & Trends
BioLineRx's Revenue history runs 2 years deep, the most recent figure standing at $194000.0 for Q4 2025.
- In Q4 2025, Revenue fell 98.35% year-over-year to $194000.0; the TTM figure through Dec 2025 stood at $1.2 million (down 95.92% YoY), while the FY2025 annual figure was $1.2 million, down 95.92% from the prior year.
- Revenue for Q4 2025 stood at $194000.0, down from $427000.0 in the prior quarter.
- The five-year high for Revenue was $11.7 million in Q4 2024, with the low at $194000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 425.49 Mn |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 | 294,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 294,000.00 |
| Mar 31, 2026 | 477,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | 6.86 Mn |